comparemela.com

Latest Breaking News On - Ameet mallik - Page 11 : comparemela.com

ADC Therapeutics SA (NYSE:ADCT) Q3 2022 Earnings Call Transcript

Operator: Welcome to the ADC Therapeutics Third Quarter 2022 Financial Results Conference Call. My name is Kevin, and I ll be your operator for today s call.

Gregory renzaKristen harrington smithJennifer herronAmanda loshbaughJoe camardoMatthew harrisonBrian chengPeter grahamKelly shiAmanda hamiltonMorgan stanleyNational cancer instituteAdc telecommunications inc old filingsSociety of hematology oncology congressExchange commissionHead of the division oncology

EC approves Zynlonta® for large B-cell lymphoma

Antibody drug conjugate Zynlonta can now be used in all European Union member states, Iceland, Norway and Liechtenstein.

Anders ullmanEuropean unionEuropean commissionDrug administrationHead of research developmentEuropean medicines agencyMedicinal productsHuman useMedical affairsChief medical officerAmeet mallikChief executive officer

Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

United statesNew jerseyUnited kingdomCity ofLausanne biopAnders ullmanPrnewswire sobiCompany on twitterEuropean commissionDrug administrationSobi investor relations teamCommittee for orphan medicinal productsEuropean unionHead of research developmentMedicinal productsHuman use

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell l

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ Sobi® and ADC Therapeutics SA today announced that the European.

United statesNew jerseyCity ofUnited kingdomLausanne biopAnders ullmanPrnewswire sobiCompany on twitterEuropean commissionDrug administrationSobi investor relations teamCommittee for orphan medicinal productsEuropean unionHead of research developmentMedicinal productsHuman use

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

/PRNewswire/ Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of.

United statesNew jerseyUnited kingdomCity ofLausanne biopAnders ullmanPrnewswire sobiEuropean commissionDrug administrationSobi investor relations teamCommittee for orphan medicinal productsEuropean unionHead of research developmentMedicinal productsHuman useEuropean medicines agency

vimarsana © 2020. All Rights Reserved.